← back to search

Eren L. Chu

Cornell University · US
Area of research
Molecular Biology
Research interest
Research interests include RNA modifications and cancer, Epigenetics and DNA Methylation, RNA Research and Splicing, and Protein Degradation and Inhibitors.
h-index
4
citations
329
works
8
NIH funding
primary concept
email

Recent publications

RNA binding protein SYNCRIP maintains proteostasis and self-renewal of hematopoietic stem and progenitor cells
Nature Communications 2023cited by 20position: middledoi
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
Nature Communications 2022cited by 28position: middledoi
HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells
Nature Communications 2020cited by 72position: middledoi
Quantitative self-assembly prediction yields targeted nanomedicines
Nature Materials 2018cited by 207position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Michael G. Kharas · Weill Cornell Medicine3 papers (2020–2023)Christina S. Leslie · Center for Cancer Research3 papers (2020–2023) · 2 papers (2020–2023)Ersilia Barin · Cornell University2 papers (2020–2023)Ly Vu · Occupational Cancer Research Centre2 papers (2020–2023)Diu Nguyen · Queen Mary University of London2 papers (2020–2023)Xuejing Yang · East China University of Political Science and Law2 papers (2020–2023)Darjus F. Tschaharganeh · Heidelberg University1 papers (2018–2018)Paolo Cifani · Lund University1 papers (2023–2023)Anas Younes · Intercept Pharmaceuticals (United States)1 papers (2022–2022)Vinagolu K. Rajasekhar · Kettering University1 papers (2018–2018)Saroj Gourkanti · University of San Diego1 papers (2020–2020) · 1 papers (2018–2018) · 1 papers (2022–2022) · 1 papers (2023–2023)Christopher R. Chin · Cornell University1 papers (2020–2020) · 1 papers (2018–2018)Camila Prieto · Memorial Sloan Kettering Cancer Center1 papers (2020–2020)John D. Chodera · Charité - Universitätsmedizin Berlin1 papers (2018–2018)Josef Leibold · STZ eyetrial1 papers (2018–2018)